At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago.

To elucidate HDAC function in oligodendrocyte development, Ye et al. 3 generated oligodendrocyte lineage-specific knockout lines by mating floxed Hdac1 and Hdac2 mice with Olig1-Cre transgenic mice.